Descamps Alexandre, Lenzi Nezha, Galtier Florence, Lainé Fabrice, Lesieur Zineb, Vanhems Philippe, Amour Sélilah, L'Honneur Anne-Sophie, Fidouh Nadhira, Foulongne Vincent, Lagathu Gisèle, Duval Xavier, Merle Corinne, Lina Bruno, Carrat Fabrice, Launay Odile, Loubet Paul
Université de Paris, Inserm CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.
Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France.
Eur Respir J. 2022 Mar 3;59(3). doi: 10.1183/13993003.00651-2021. Print 2022 Mar.
The purpose of this study was to describe the clinical characteristics and in-hospital and post-discharge outcomes of respiratory syncytial virus (RSV) infection among adults hospitalised with influenza-like illness (ILI) and compared against patients admitted for influenza.
Adults hospitalised with ILI were prospectively included from five French university hospitals over two consecutive winter seasons (2017/2018 and 2018/2019). RSV and influenza virus were detected by multiplex reverse transcription PCR on nasopharyngeal swabs. RSV-positive patients were compared to RSV-negative and influenza-positive hospitalised patients. Poisson regression models were used to estimate the adjusted prevalence ratio (aPR) associated with in-hospital and post-discharge outcomes between RSV and influenza infections. The in-hospital outcome was a composite of the occurrence of at least one complication, length of stay ≥7 days, intensive care unit admission, use of mechanical ventilation and in-hospital death. Post-discharge outcome included 30- and 90-day all-cause mortality and 90-day readmission rates.
Overall, 1428 hospitalised adults with ILI were included. RSV was detected in 8% (114 of 1428) and influenza virus in 31% (437 of 1428). Patients hospitalised with RSV were older than those with influenza (mean age 73.0 68.8 years, p=0.015) with a higher frequency of chronic respiratory or cardiac disease (52% 39%, p=0.012, and 52% 41%, p=0.039, respectively) and longer hospitalisation duration (median stay 8 6 days, p<0.001). Anti-influenza therapies were less prescribed among RSV patients than influenza patients (20% 66%, p<0.001). In-hospital composite outcome was poorer in RSV patients (aPR 1.5, 95% CI 1.1-2.1) than in those hospitalised with influenza. No difference was observed for the post-discharge composite outcome (aPR 1.1, 95% CI 0.8-1.6).
RSV infection results in serious respiratory illness, with worse in-hospital outcomes than influenza and with similar midterm post-discharge outcomes.
本研究旨在描述流感样疾病(ILI)住院成人中呼吸道合胞病毒(RSV)感染的临床特征、住院期间及出院后的结局,并与流感住院患者进行比较。
在连续两个冬季(2017/2018年和2018/2019年)从五家法国大学医院前瞻性纳入ILI住院成人。通过对鼻咽拭子进行多重逆转录PCR检测RSV和流感病毒。将RSV阳性患者与RSV阴性及流感阳性住院患者进行比较。采用泊松回归模型估计RSV感染与流感感染之间与住院期间及出院后结局相关的调整患病率比(aPR)。住院结局是至少发生一种并发症、住院时间≥7天、入住重症监护病房、使用机械通气及住院死亡的综合情况。出院后结局包括30天和90天全因死亡率以及90天再入院率。
总体而言,纳入了1428例ILI住院成人。检测到RSV的占8%(1428例中的114例),检测到流感病毒的占31%(1428例中的437例)。RSV住院患者比流感患者年龄更大(平均年龄73.0对68.8岁,p = 0.015),慢性呼吸道或心脏病的发生率更高(分别为52%对39%,p = 0.012,以及52%对41%,p = 0.039),住院时间更长(中位住院时间8对6天,p < 0.001)。RSV患者接受抗流感治疗的比例低于流感患者(20%对66%,p < 0.001)。RSV患者的住院综合结局比流感住院患者更差(aPR 1.5,95% CI 1.1 - 2.1)。出院后综合结局未观察到差异(aPR 1.1,95% CI 0.8 - 1.6)。
RSV感染导致严重的呼吸道疾病,住院结局比流感更差,但出院中期结局相似。